Irritable bowel syndrome with diarrhea
Information
- Disease name
- Irritable bowel syndrome with diarrhea
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05702255 | Completed | N/A | Self- Administered Acupressure for Diarrhea Predominant Irritable Bowel Syndrome | February 5, 2023 | August 28, 2023 |
| NCT01177410 | Completed | Phase 2 | Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea | July 2010 | August 2011 |
| NCT01303224 | Completed | Phase 2 | Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) | October 2010 | July 2012 |
| NCT01497847 | Completed | Post-Infectious Irritable Bowel Syndrome (PI-IBS) | March 2010 | February 2013 | |
| NCT01543178 | Completed | Phase 3 | Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study | February 2012 | June 2014 |
| NCT02107196 | Completed | Phase 3 | 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | March 2014 | June 2015 |
| NCT00552565 | Completed | Phase 3 | Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) | September 2007 | June 2009 |
| NCT03997708 | Completed | N/A | A Mediterranean Approach to Low FODMAP Diet (MED-LFD) for Managing IBS Symptoms | July 1, 2019 | April 3, 2023 |
| NCT04053790 | Completed | Phase 4 | Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D) | January 15, 2019 | January 29, 2023 |
| NCT04129619 | Completed | Phase 2 | A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) | November 22, 2019 | October 4, 2021 |
| NCT04484467 | Completed | N/A | Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome | February 9, 2018 | December 28, 2019 |
| NCT04557215 | Completed | Phase 1/Phase 2 | Efficacy and Safety of Rifaximin With NAC in IBS-D | November 13, 2020 | October 30, 2022 |
| NCT04662957 | Completed | N/A | Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome | November 2, 2019 | May 31, 2020 |
| NCT04899869 | Completed | N/A | Faecal Microbiota Transplantation in Irritable Bowel Syndrome | June 17, 2021 | April 29, 2024 |
| NCT04950296 | Completed | N/A | To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome | September 16, 2021 | May 5, 2022 |
| NCT05130047 | Completed | Phase 2 | Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) | December 1, 2021 | November 8, 2022 |
| NCT05277428 | Completed | N/A | Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1 | November 1, 2020 | January 29, 2022 |
| NCT05867550 | Completed | Phase 4 | To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea | January 3, 2023 | June 10, 2023 |
| NCT05339243 | Completed | N/A | Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome | April 21, 2022 | January 13, 2023 |
| NCT05523427 | Completed | N/A | Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome | July 19, 2022 | January 6, 2023 |
| NCT02431533 | Completed | N/A | The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome | January 2016 | August 2018 |
| NCT02757105 | Completed | Phase 2 | Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) | May 19, 2016 | July 14, 2017 |
| NCT02822118 | Completed | Phase 1/Phase 2 | Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea | January 2013 | May 2016 |
| NCT02959983 | Completed | Phase 4 | Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use | October 25, 2016 | January 22, 2018 |
| NCT03245645 | Completed | N/A | FODMAP Reintroduction in Irritable Bowel Syndrome | March 24, 2017 | June 30, 2023 |
| NCT03270085 | Completed | Phase 2 | Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption | December 7, 2017 | May 31, 2019 |
| NCT03441581 | Completed | Phase 4 | Eluxadoline Bile Acid Malabsorption (BAM) Study | February 23, 2018 | April 28, 2020 |
| NCT03557788 | Completed | Phase 4 | Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome | May 7, 2018 | August 13, 2021 |
| NCT06432569 | Enrolling by invitation | N/A | Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1) | March 8, 2024 | December 30, 2025 |
| NCT05719896 | Not yet recruiting | Phase 2 | Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea | February 2023 | December 2024 |
| NCT06297421 | Not yet recruiting | Phase 2 | Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults | August 2024 | June 2026 |
| NCT05646186 | Recruiting | N/A | Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome | October 1, 2022 | December 31, 2023 |
| NCT06123234 | Recruiting | N/A | Randomised Double-blind Active vs. Placebo Clinical Trial on the Effect of a Food Supplement on IBS-D in Children | April 1, 2023 | April 1, 2025 |
| NCT05754177 | Recruiting | N/A | Safety and Efficacy of a Probiotic Supplement in IBS-D | June 6, 2023 | December 15, 2024 |
| NCT05453916 | Recruiting | Phase 1/Phase 2 | Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation | July 1, 2022 | December 31, 2024 |
| NCT04806386 | Recruiting | N/A | The Role of Fiber in the Prevention and Treatment of Fecal Incontinence | July 21, 2021 | October 1, 2024 |
| NCT03729271 | Recruiting | Phase 4 | Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea | January 9, 2020 | January 1, 2025 |
| NCT06247046 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D | March 16, 2024 | January 2027 |
| NCT04830410 | Recruiting | N/A | The Effects of Carbohydrates in Irritable Bowel Syndrome | March 30, 2021 | December 2024 |
| NCT04855799 | Recruiting | Phase 2 | GI Permeability Change in Response to Aquamin® | November 2, 2021 | January 2025 |
| NCT06153420 | Recruiting | Phase 2 | Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). | December 28, 2023 | May 4, 2025 |
| NCT02120027 | Terminated | Phase 3 | 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | February 2014 | November 2015 |
| NCT05379036 | Unknown status | Phase 4 | Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome | June 23, 2021 | May 31, 2022 |
| NCT05311293 | Unknown status | Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis | November 1, 2021 | December 2023 | |
| NCT04492787 | Unknown status | Phase 2 | Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) | June 6, 2020 | October 30, 2022 |
| NCT04214470 | Unknown status | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS | March 2, 2020 | July 2023 | |
| NCT03806959 | Unknown status | N/A | Interest of Pan-capsule in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy | November 7, 2018 | June 30, 2021 |
| NCT03221790 | Unknown status | N/A | Effect of FODMAPs on Mucosal Inflammation in IBS Patients | November 1, 2017 | February 1, 2019 |
| NCT02320318 | Withdrawn | Phase 3 | 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | October 2015 | December 2016 |
- MedGen concept unique identifier (MedGen Concept name)
- C0348898
- MedGen unique identifier (MedGen Concept name)
- 578523